...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Annals of Emergency Medicine: Journal of the American College of Emergency Physicians and the University Association for Emergency Medicine >Ibuprofen Prevents Altitude Illness: A Randomized Controlled Trial for Prevention of Altitude Illness With Nonsteroidal Anti-inflammatories
【24h】

Ibuprofen Prevents Altitude Illness: A Randomized Controlled Trial for Prevention of Altitude Illness With Nonsteroidal Anti-inflammatories

机译：布洛芬预防高原病：一项非甾体类抗炎药预防高原病的随机对照试验

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Study objective: Acute mountain sickness occurs in more than 25% of the tens of millions of people who travel to high altitude each year. Previous studies on chemoprophylaxis with nonsteroidal anti-inflammatory drugs are limited in their ability to determine efficacy. We compare ibuprofen versus placebo in the prevention of acute mountain sickness incidence and severity on ascent from low to high altitude.Methods: Healthy adult volunteers living at low altitude were randomized to ibuprofen 600 mg or placebo 3 times daily, starting 6 hours before ascent from 1,240 m (4,100 ft) to 3,810 m (12,570 ft) during July and August 2010 in the White Mountains of California. The main outcome measures were acute mountain sickness incidence and severity, measured by the Lake Louise Questionnaire acute mountain sickness score with a diagnosis of >= 3 with headache and 1 other symptom.Results: Eighty-six participants completed the study; 44 (51%) received ibuprofen and 42 (49%) placebo. There were no differences in demographic characteristics between the 2 groups. Fewer participants in the ibuprofen group (43%) developed acute mountain sickness compared with those receiving placebo (69%) (odds ratio 0.3, 95% confidence interval 0.1 to 0.8; number needed to treat 3.9, 95% confidence interval 2 to 33). The acute mountain sickness severity was higher in the placebo group (4.4 [SD 2.6]) than individuals receiving ibuprofen (3.2 [SD 2.4]) (mean difference 0.9%; 95% confidence interval 0.3% to 3.0%).Conclusion: Compared with placebo, ibuprofen was effective in reducing the incidence of acute mountain sickness.
机译：研究目标：每年上千万的高海拔人群中，超过25％的人患有急性高山病。先前使用非甾体类抗炎药进行化学预防的研究在确定疗效的能力方面受到限制。我们比较了布洛芬和安慰剂在预防从低空到高空上升的急性高山病的发生率和严重性方面的方法。方法：从低空上升到健康的成年志愿者，每天3次，每天3次，随机从布洛芬600 mg或安慰剂随机分配， 2010年7月至8月，在加利福尼亚怀特山的1,240 m（4,100 ft）至3,810 m（12,570 ft）。主要结局指标为急性高山病的发生率和严重程度，通过路易斯湖问卷调查的急性高山病得分进行评估，诊断为≥= 3并伴有头痛和其他1种症状。结果：86名参与者完成了研究; 44（51％）位接受布洛芬和42（49％）位安慰剂。两组之间的人口统计学特征没有差异。与接受安慰剂的患者（69％）相比，布洛芬组的参与者出现急性山区疾病的比例较低（43％）（赔率0.3，95％的置信区间为0.1至0.8;需要治疗的人数为3.9，95％的置信区间为2至33） 。安慰剂组的急性高山病严重程度（4.4 [SD 2.6]）高于接受布洛芬的个体（3.2 [SD 2.4]）（平均差异0.9％; 95％置信区间0.3％至3.0％）。安慰剂布洛芬可有效减少急性山区疾病的发生。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号